In conclusion, our data supported the combination of abemaciclib and gilteritinib as an excellent therapeutic candidate for treatment of lung cancer, whereby the combined treatment displays greater cytotoxicity by inhibiting Rb, AKT, DNA replication and HR-associated genes expression than either drug. Here, RB1 is linked to lung cancer.